Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinwen Shan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Computer-Aided Drug Design|July 6, 2019
MolOpt: A Web Server for Drug Design using Bioisosteric TransformationJinwen Shan, Changge Ji
Journal of Chemical Information and Modeling|December 4, 2020
FragRep: A Web Server for Structure-Based Drug Design by Fragment ReplacementJinwen Shan, Xiaolin Pan, Xingyu Wang, et al.
Breast Cancer Research : BCR|August 14, 2023
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer modelsFeng Zhou, Guimei Yang, Liting Xue, et al.
Medcomm|September 23, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumorsZhiyong Yu, Yi Kuang, Liting Xue, et al.
Journal of Medicinal Chemistry|December 30, 2025
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer TherapyWei Zhu, Lei Jiang, Dongxing Zhu, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Computer-Aided Drug Design|July 6, 2019
MolOpt: A Web Server for Drug Design using Bioisosteric TransformationJinwen Shan, Changge Ji
Journal of Chemical Information and Modeling|December 4, 2020
FragRep: A Web Server for Structure-Based Drug Design by Fragment ReplacementJinwen Shan, Xiaolin Pan, Xingyu Wang, et al.
Breast Cancer Research : BCR|August 14, 2023
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer modelsFeng Zhou, Guimei Yang, Liting Xue, et al.
Medcomm|September 23, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumorsZhiyong Yu, Yi Kuang, Liting Xue, et al.
Journal of Medicinal Chemistry|December 30, 2025
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer TherapyWei Zhu, Lei Jiang, Dongxing Zhu, et al.
Pageof 1